Merck (MRK) is a publicly traded Healthcare sector company. As of October 13, 2026, MRK trades at $145.74 with a market cap of $359.22B and a P/E ratio of 112.56. MRK moved -0.10% today. Year to date, MRK is +38.18%; over the trailing twelve months it is +69.15%. Its 52-week range spans $73.31 to $156.92. Analyst consensus is buy with an average price target of $160.40. Rallies surfaces MRK's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Street View: Merck eye disease drug matches Roche's therapy in study, analysts cautious: Merck said experimental drug remigromig met its non-inferiority goal against Roche's Lucentis in a mid-to-late-stage diabetic macular edema trial, with patients gaining 8.7 to 9.1 vision-test letters after one year versus 11.8 with Lucentis. Analysts questioned its differentiation, and Jefferies cut its risk-adjusted sales estimate to about $300 million from $750 million.
| Metric | Value |
|---|---|
| Price | $145.74 |
| Market Cap | $359.22B |
| P/E Ratio | 112.56 |
| EPS | $1.27 |
| Dividend Yield | 0.85% |
| 52-Week High | $156.92 |
| 52-Week Low | $73.31 |
| Volume | 5.06M |
| Avg Volume | 0 |
| Revenue (TTM) | $66.57B |
| Net Income | $3.17B |
| Gross Margin | 72.97% |
21 analysts cover MRK: 0 strong buy, 14 buy, 7 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $160.40.